DOCSLIB.ORG

Therapy Focus – J&J Confirms Hope for New Mechanism in Depression

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Therapy Focus – J&J Confirms Hope for New Mechanism in Depression May 09, 2018 Therapy focus – J&J confirms hope for new mechanism in depression Amy Brown The first look at late-stage data on Johnson & Johnson’s hotly-tipped novel antidepressant esketamine came at a medical conference last weekend, and the results were not quite as strong as many were hoping to see. Encouraging signals could be certainly be found, however, and J&J seems undeterred from trying to seek regulatory approval. Others pursing NMDA modulation in depression are also likely to draw comfort in the results, which provide the first phase III validation of this mechanism, and a clear bar to beat (see table below). Hopes for esketamine and other products like it lie in their similarity to ketamine, which at low doses displays antidepressant effects that kick in very quickly. Traditional antidepressants which act via the serotonergic system – selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) – can take weeks to have an effect; a large proportion of patients fail to respond at all. Hence the need for both faster acting agents – for example in suicidal patients – and novel mechanisms to treat those who need different options. A new target NMDA receptor modulation is a novel mechanism in depression. Over the last decade researchers have become increasingly convinced that dysregulation of glutamate, a neurotransmitter which signals through NMDA, plays an important role in the condition. This system is already known to be a factor in cognitive function and neurodegeneration and Namenda, the NMDA antagonist mematine, has been available as a treatment for Alzheimer’s dementia for several years. In depression, it is thought that blocking NMDA receptors can improve brain plasticity and strengthen synaptic connections. Ketamine works via this mechanism but its psychotomimetic properties – it can cause dissociation and hallucinations, for example – limit its use in medical practice. Knowledge of ketamine’s potential spurred a quest to find similar compounds with different side-effect profiles, but the same rapid onset. J&J has come the furthest to date and is running a substantial clinical programme with esketamine. The drug is an enantiomer of ketamine – effectively a mirror image of the original molecule – and the big question is whether it is different enough to shake off the side effect profile. Esketamine phase III programme - active trials Acronym Status Enrollment NCT ID Primary Completion Date Sustain-1 Active, not recruiting 718 NCT02493868 Mar-18 Transform-1 Completed 346 NCT02417064 Feb-18 Transform-2 Completed 236 NCT02418585 Reported Transform-3 Completed 139 NCT02422186 Reported Sustain-2 Completed 821 NCT02497287 Oct-17 - Recruiting 1,150 NCT02782104 Aug-21 - Recruiting 224 NCT03039192 Sep-19 - Recruiting 224 NCT03097133 Sep-19 Source: clinicaltrials.gov Data released at the American Psychiatric Association annual meeting over the weekend suggest there are lingering doubts. Dissociation was one of the most common adverse events reported, though in less than 10% of patients. And efficacy is still a big concern. Of the two trials reported, only one, Transform-2, which tested esketamine in adult patients, met the primary endpoint. Also worryingly, this study missed significance in its first key secondary endpoint, which rendered all further secondary readings exploratory. A second trial, Transform-3, in elderly patients with treatment-resistant depression, narrowly missed significance on its primary endpoint. J&J maintained that the trials showed esketamine can produce a rapid effect, and with breakthrough therapy designation in treatment-resistant depression and major depressive disorder with imminent risk for suicide, the company appears to believe that esketamine can convince the regulators. With other trials underway and a filing possible in the second half of this year, the question is whether the FDA will want to see more evidence. Prominent projects targeting NMDA - a novel mechanism in depression Product Company Mechanism of Action Ongoing trials Phase III Esketamine Johnson & Johnson NMDA receptor antagonist See above NCT02932943; NCT02943564; Rapastinel Allergan NMDA receptor partial agonist NCT02932943 Phase II VistaGen NMDA receptor glycine B AV-101 NCT03078322 Therapeutics antagonist CERC-301 Cerecor NMDA receptor 2B antagonist NCT02459236 (completed) Source: EvaluatePharma, company statements As the closest competitor in this field, Allergan will be scrutinising J&J’s data closely. Allergan’s agent rapastinel is in two phase III trials, though data are unlikely to emerge until next year. The compound works slightly differently to esketamine in that its blocks the glycine-binding site on the NMDA receptor. Allergan believes this should result in a much more benign side-effect profile. Rapastinel is injected, while esketamine is delivered via a nasal spray. Vistagen’s AV-101 also targets the glycine-binding site. The California company started a large phase II study last month called Elevate, which should read out early next year. Others have approached NMDA modulation via another receptor subunit called NR2B. CERC-101, a compound originally discovered by Merck but which was taken on by Cerecor, appears to be the only asset left in development, though the company recently switched its focus to orphan neurological conditions. Two phase II trials failed to establish a therapeutic window, although the agent was found to be safe. Others targeting NR2B have also failed – Pfizer scrapped traxoprodil on heart safety concerns a few years ago – and it seems that for now this approach has run out of steam. Thus the main contenders chasing J&J are Allergan and Vistagen. Both are due to unveil their data next year, and both will be looking to generate stronger efficacy and fewer side effects. At least esketamine is well ahead of the pack and has generated one positive pivotal trial – against an active comparator – which in this field should not be brushed off lightly. To contact the writer of this story email Amy Brown in London at [email protected] or follow @ByAmyBrown on Twitter. More from Evaluate Vantage Evaluate HQ 44-(0)20-7377-0800 Evaluate Americas +1-617-573-9450 Evaluate APAC +81-(0)80-1164-4754 © Copyright 2021 Evaluate Ltd..
Load more

Recommended publications
  • Sciatica and Chronic Pain
    Sciatica and Chronic Pain Past, Present and Future Robert W. Baloh 123 Sciatica and Chronic Pain Robert W. Baloh Sciatica and Chronic Pain Past, Present and Future Robert W. Baloh, MD Department of Neurology University of California, Los Angeles Los Angeles, CA, USA ISBN 978-3-319-93903-2 ISBN 978-3-319-93904-9 (eBook) https://doi.org/10.1007/978-3-319-93904-9 Library of Congress Control Number: 2018952076 © Springer International Publishing AG, part of Springer Nature 2019 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors, and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
    [Show full text]
  • A Human Stem Cell-Derived Test System for Agents Modifying Neuronal N
    Archives of Toxicology (2021) 95:1703–1722 https://doi.org/10.1007/s00204-021-03024-0 IN VITRO SYSTEMS A human stem cell‑derived test system for agents modifying neuronal 2+ N‑methyl‑D‑aspartate‑type glutamate receptor Ca ‑signalling Stefanie Klima1,2 · Markus Brüll1 · Anna‑Sophie Spreng1,3 · Ilinca Suciu1,3 · Tjalda Falt1 · Jens C. Schwamborn4 · Tanja Waldmann1 · Christiaan Karreman1 · Marcel Leist1,5 Received: 28 October 2020 / Accepted: 4 March 2021 / Published online: 13 March 2021 © The Author(s) 2021 Abstract Methods to assess neuronal receptor functions are needed in toxicology and for drug development. Human-based test systems that allow studies on glutamate signalling are still scarce. To address this issue, we developed and characterized pluripotent stem cell (PSC)-based neural cultures capable of forming a functional network. Starting from a stably proliferating neu- roepithelial stem cell (NESC) population, we generate “mixed cortical cultures” (MCC) within 24 days. Characterization by immunocytochemistry, gene expression profling and functional tests (multi-electrode arrays) showed that MCC contain various functional neurotransmitter receptors, and in particular, the N-methyl-D-aspartate subtype of ionotropic glutamate receptors (NMDA-R). As this important receptor is found neither on conventional neural cell lines nor on most stem cell- derived neurons, we focused here on the characterization of rapid glutamate-triggered Ca2+ signalling. Changes of the intra- 2+ cellular free calcium ion concentration ([Ca ]i) were measured by fuorescent imaging as the main endpoint, and a method to evaluate and quantify signals in hundreds of cells at the same time was developed. We observed responses to glutamate in the low µM range.
    [Show full text]
  • Advances in Non-Dopaminergic Treatments for Parkinson's Disease
    REVIEW ARTICLE published: 22 May 2014 doi: 10.3389/fnins.2014.00113 Advances in non-dopaminergic treatments for Parkinson’s disease Sandy Stayte 1,2 and Bryce Vissel 1,2* 1 Neuroscience Department, Neurodegenerative Disorders Laboratory, Garvan Institute of Medical Research, Sydney, NSW, Australia 2 Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia Edited by: Since the 1960’s treatments for Parkinson’s disease (PD) have traditionally been directed Eero Vasar, University of Tartu, to restore or replace dopamine, with L-Dopa being the gold standard. However, chronic Estonia L-Dopa use is associated with debilitating dyskinesias, limiting its effectiveness. This has Reviewed by: resulted in extensive efforts to develop new therapies that work in ways other than Andrew Harkin, Trinity College Dublin, Ireland restoring or replacing dopamine. Here we describe newly emerging non-dopaminergic Sulev Kõks, University of Tartu, therapeutic strategies for PD, including drugs targeting adenosine, glutamate, adrenergic, Estonia and serotonin receptors, as well as GLP-1 agonists, calcium channel blockers, iron Pille Taba, Universoty of Tartu, chelators, anti-inflammatories, neurotrophic factors, and gene therapies. We provide a Estonia Pekka T. Männistö, University of detailed account of their success in animal models and their translation to human clinical Helsinki, Finland trials. We then consider how advances in understanding the mechanisms of PD, genetics, *Correspondence: the possibility that PD may consist of multiple disease states, understanding of the Bryce Vissel, Neuroscience etiology of PD in non-dopaminergic regions as well as advances in clinical trial design Department, Neurodegenerative will be essential for ongoing advances. We conclude that despite the challenges ahead, Disorders Laboratory, Garvan Institute of Medical Research, patients have much cause for optimism that novel therapeutics that offer better disease 384 Victoria Street, Darlinghurst, management and/or which slow disease progression are inevitable.
    [Show full text]
  • Changes in Glutamate Levels Measured by Glutamate
    Changes in glutamate levels measured by glutamate voltammetry in the rat medial prefrontal cortex after treatment with N-methyl-D-aspartate receptor antagonists (P.1.g.023) Irina Ionescu, Kelly Allers, Roberto Arban, Cornelia Dorner-Ciossek and Lothar Kussmaul Boehringer Ingelheim, CNS Diseases Research Background Hypothesized antidepressant MoA of NMDA-R antagonists: Disinhibition of glutamatergic neurons in the PFC N-methyl-D-aspartate receptor (NMDA-R) have been described as potential novel treatment options in the therapy of treatment-reistant depression (TRD). A single sub-anesthetic dose of the noncompetitive NMDA-R antagonist GABA ketamine has been shown to exert rapid-onset and long-lasting antidepressant Glutamate Glutamate NMDA-R effects in TRD patients; these effects were accompanied by brief psychotic Increased glutamate release episodes. Fast-onset antidepressant effects without psychotic side effects have also been described in the clinic for the NR2B-selective negative allosteric modulator (NAM) traxoprodil. However, other unspecific NMDA-R blockers, Synaptic plasticity such as lanicemine, failed to show fast-onset long-lasting antidepressant NMDA-R antagonists (ketamine, traxoprodil) effects in the clinic after single application. Here, we used glutamate AMPA-R AMPA-R voltammetry in rats in order to identify a preclinical predictor of clinical efficacy The increase in glutamate release as proof of circuit by circuit engagement in the prefrontal cortex (PFC). engagement and antidepressant activity can be measured by glutamate voltammetry. Using glutamate voltammetry to show circuit engagement by clinically active NMDA-R antagonists in the PFC Glutamate biosensor (Pinnacle Technology Inc., USA) Advantages of glutamate voltammetry Experimental design - fast response time Experiments were performed in Wistar Han rats implanted with Recording site: PFC - fast sampling time (1 Hz) guide cannulae at the specified coordinates.
    [Show full text]
  • Ketamine: a Novel Antidepressant with a Fast Onset of Action?† COMMENTARY ON… COCHRANE CORNER Katharine Smith & Mary Jane Attenburrow
    BJPsych Advances (2016), vol. 22, 216–221 doi: 10.1192/apt.22.4.216 ROUND THE CORNER Ketamine: a novel antidepressant with a fast onset of action?† COMMENTARY ON… COCHRANE CORNER Katharine Smith & Mary Jane Attenburrow Katharine Smith is an honorary For bipolar depression, the treatment challenge SUMMARY consultant psychiatrist at the is even greater. There is scarce evidence that National Institute for Health Glutamate receptor modulators, including antidepressants are effective as a first-line Research (NIHR) Oxford cognitive ketamine, are possible candidates for new health Clinical Research Facility treatment (Sidor 2012), and mood instability is an antidepressants with a novel mode of action. and Oxford University Department additional challenge. Current recommendations The pair of reviews discussed in this month’s of Psychiatry. Mary Jane (Kendall 2014) focus on the use of quetiapine; Attenburrow is Clinical Lead at Round the Corner considered their use in treating the NIHR Oxford cognitive health unipolar major depression and bipolar depression. lamotrigine, fluoxetine plus olanzapine and Clinical Research Facility, a Senior Promising results were seen for ketamine, but lithium are also recommended. A recent trial Research Fellow at Oxford University further studies are needed, in particular to (CEQUEL) demonst ra ted that there may be benefit Department of Psychiatry and an investigate whether the benefits are sustained in the combination of lamotrigine with quetiapine honorary consultant psychiatrist. Correspondence Dr Katharine or can be extended by repeated or adjunctive (Geddes 2016). Smith, NIHR Oxford cognitive health treatment, whether ketamine is effective in Although the differences in treatment response Clinical Research Facility, Warneford treatment resistance, whether other modes of between unipolar and bipolar depression Hospital, Oxford OX3 7JX, UK.
    [Show full text]
  • Traxoprodil, a Selective Antagonist of the NR2B Subunit of the NMDA
    Metab Brain Dis (2016) 31:803–814 DOI 10.1007/s11011-016-9810-5 ORIGINAL ARTICLE Traxoprodil, a selective antagonist of the NR2B subunit of the NMDA receptor, potentiates the antidepressant-like effects of certain antidepressant drugs in the forced swim test in mice Ewa Poleszak1 & Weronika Stasiuk 2 & Aleksandra Szopa1 & Elżbieta Wyska3 & Anna Serefko1 & Anna Oniszczuk4 & Sylwia Wośko 1 & Katarzyna Świąder1 & Piotr Wlaź5 Received: 25 November 2015 /Accepted: 17 February 2016 /Published online: 29 February 2016 # The Author(s) 2016. This article is published with open access at Springerlink.com Abstract One of the newest substances, whose antidepres- these changes were not due to the severity of locomotor ac- sant activity was shown is traxoprodil, which is a selective tivity. The observed effect of traxoprodil is only partially as- antagonist of the NR2B subunit of the NMDA receptor. The sociated with serotonergic system and is independent of the main goal of the present study was to evaluate the effect of effect on the 5-HT1A and 5-HT2 serotonin receptors. The re- traxoprodil on animals’ behavior using the forced swim test sults of an attempt to assess the nature of the interaction be- (FST), as well as the effect of traxoprodil (10 mg/kg) on the tween traxoprodil and the tested drugs show that in the case of activity of antidepressants, such as imipramine (15 mg/kg), joint administration of traxoprodil and fluoxetine, imip- fluoxetine (5 mg/kg), escitalopram (2 mg/kg) and reboxetine ramine or escitalopram, there were interactions in the (2.5 mg/kg). Serotonergic lesion and experiment using the pharmacokinetic phase.
    [Show full text]
  • NMDA) Receptor Antagonist
    White Paper The Use of Robust Biomarkers in the Early Clinical Development of N-methyl-D-aspartate (NMDA) Receptor Antagonist Biotrial has extensive early clinical development experience with a high output of over 20 CNS studies per year. The experience and capabilities of Biotrial Neuroscience (now also incorporating the know-how of the legacy CNS CRO Forenap), enables the in-depth cognitive and neurophysiological assessment of NMDA antagonists. The aim of the present document is twofold. Firstly, to characterize the pharmacological effects of non-competitive NMDA antagonists in psychiatry and pain indications and to validate the use of ketamine as a positive control in the development of these compounds with this mechanism of action. Secondly, to present Biotrial’s strategy and rationale for the integration of surrogate endpoints, biomarkers and PD models into a Phase I program, in order to establish early proof of concept of new NMDA antagonist candidates. Pharmacological Effects of Non-Competitive NMDA Antagonists: The Example of Ketamine Glutamatergic antagonists, such as ketamine, acting at the NMDA open channel have a long history of use in neuropsychiatry – independently of their anesthetic or pain attenuating properties. The mechanism of action and pharmacological effects of ketamine have been extensively studied over the last 20 years. Ketamine was initially profiled as a reversible model of psychosis1, producing positive and negative symptoms of schizophrenia as well as cognitive impairment. As of today there are approximately one hundred publications on the symptoms, brain connectivity, imaging and cognitive function alterations induced by ketamine. The main hypothesis to explain the effect of ketamine was the reduction of the glutamatergic burst in the prefrontal cortex, secondarily enhancing AMPA α-(amino- 3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor) signaling.
    [Show full text]
  • Understanding History, and Not Repeating It. Neuroprotection For
    Clinical Neurology and Neurosurgery 129 (2015) 1–9 Contents lists available at ScienceDirect Clinical Neurology and Neurosurgery jo urnal homepage: www.elsevier.com/locate/clineuro Review Understanding history, and not repeating it. Neuroprotection for acute ischemic stroke: From review to preview a a b b,c a,b,c,d,∗ Stephen Grupke , Jason Hall , Michael Dobbs , Gregory J. Bix , Justin F. Fraser a Department of Neurosurgery, University of Kentucky, Lexington, USA b Department of Neurology, University of Kentucky, Lexington, USA c Department of Anatomy and Neurobiology, University of Kentucky, Lexington, USA d Department of Radiology, University of Kentucky, Lexington, USA a r t i c l e i n f o a b s t r a c t Article history: Background: Neuroprotection for ischemic stroke is a growing field, built upon the elucidation of the Received 17 April 2014 biochemical pathways of ischemia first studied in the 1970s. Beginning in the early 1990s, means by Received in revised form 7 November 2014 which to pharmacologically intervene and counteract these pathways have been sought, though with Accepted 13 November 2014 little clinical success. Through a comprehensive review of translations from laboratory to clinic, we aim Available online 3 December 2014 to evaluate individual mechanisms of action, while highlighting potential barriers to success that will guide future research. Keywords: Methods: The MEDLINE database and The Internet Stroke Center clinical trials registry were queried Acute stroke Angiography for trials involving the use of neuroprotective agents in acute ischemic stroke in human subjects. For the purpose of the review, neuroprotective agents refer to medications used to preserve or protect the Brain ischemia Drug trials potentially ischemic tissue after an acute stroke, excluding treatments designed to re-establish perfusion.
    [Show full text]
  • Ep 2932971 A1
    (19) TZZ ¥ __T (11) EP 2 932 971 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 21.10.2015 Bulletin 2015/43 A61K 31/54 (2006.01) A61K 31/445 (2006.01) A61K 9/08 (2006.01) A61K 9/51 (2006.01) (2006.01) (21) Application number: 15000954.6 A61L 31/00 (22) Date of filing: 06.03.2006 (84) Designated Contracting States: • MCCORMACK, Stephen, Joseph AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Claremont, CA 91711 (US) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • SCHLOSS, John, Vinton SK TR Valencia, CA 91350 (US) • NAGY, Anna Imola (30) Priority: 04.03.2005 US 658207 P Saugus, CA 91350 (US) • PANANEN, Jacob, E. (62) Document number(s) of the earlier application(s) in 306 Los Angeles, CA 90042 (US) accordance with Art. 76 EPC: 06736872.0 / 1 861 104 (74) Representative: Ali, Suleman et al Avidity IP Limited (71) Applicant: Otonomy, Inc. Broers Building, Hauser Forum San Diego, CA 92121 (US) 21 JJ Thomson Avenue Cambridge CB3 0FA (GB) (72) Inventors: • LOBL, Thomas, Jay Remarks: Valencia, This application was filed on 09-04-2015 as a CA 91355-1995 (US) divisional application to the application mentioned under INID code 62. (54) KETAMINE FORMULATIONS (57) Formulations of ketamine for administration to the inner or middle ear. EP 2 932 971 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 932 971 A1 Description [0001] This application claims the benefit of Serial No. 60/658,207 filed March 4, 2005.
    [Show full text]
  • A7471055 Treatment Access Protocol For
    Dacomitinib A7471055 Protocol, 28 January 2015 CLINICAL PROTOCOL — A7471055 TREATMENT ACCESS PROTOCOL FOR PATIENTS PREVIOUSLY TREATED WITH DACOMITINIB ON A CLINICAL TRIAL IN JAPAN Compound: PF-00299804 Compound Name: Dacomitinib United States (US) Investigational New CCI Drug (IND) Number: European Clinical Trials Database N/A (EudraCT) Number: Protocol Number: A7471055 Phase: Phase 2 Page 1 Dacomitinib A7471055 Protocol, 28 January 2015 Document History Document Version Date Summary of Changes Original Protocol 28 January 2015 Not Applicable (N/A) Page 2 Dacomitinib A7471055 Protocol, 28 January 2015 Abbreviations Abbreviation Term AE adverse event ALT alanine transaminase AST aspartate transaminase ATP adenosine triphosphate BUN blood urea nitrogen CRF case report form CSA clinical study agreement CSR clinical study report CTCAE Common Terminology Criteria for Adverse Events DAI dosage and administration instructions DMC data monitoring committee DVT deep vein thrombosis EC ethics committee ECG Electrocardiogram ECOG Eastern Cooperative Group EDP exposure during pregnancy EGFR epidermal growth factor receptor EDTA edetic acid (ethylenediaminetetraacetic acid) GCP Good Clinical Practice HDPE High Density PolyEthylene HER Human Epidermal Growth Factor receptor IB Investigator’s Brochure ICH International Conference on Harmonisation ID Identification IEC institutional ethics committee IND investigational new drug application INR international normalized ratio IRB institutional review board IUD intrauterine device KRAS Kirsten Rat Sarcoma
    [Show full text]
  • Correspondence
    Psychological Medicine (2016), 46, 2449–2451. © Cambridge University Press 2016 Correspondence Psychological Medicine, 46 (2016). Hashimoto, 2014;Yanget al. 2015). Furthermore, a sin- doi:10.1017/S0033291716000969 gle dose of esketamine, but not R-ketamine, resulted in First published online 10 June 2016 loss of parvalbumin (PV)-immunoreactivity in the pre- frontal cortex (Yang et al. 2015). A recent study using R-ketamine: a rapid-onset and sustained [11C]raclopride and positron emission tomography antidepressant without risk of brain toxicity showed a marked reduction of dopamine D2/3 receptor binding in the conscious monkey striatum after single infusion of esketamine, but not R-ketamine (Hashimoto et al. 2016). Singh et al. (2015) reported I read with great interest the recent article by Kishimoto that psychotomimetic side effects were the highest at et al. (2016) about meta-analysis of the antidepressant 40 min after single infusion of esketamine although a effects of the N-methyl-D-aspartate receptor (NMDA-R) rapid-onset antidepressant effect was shown in antagonist ketamine (racemate) and non-ketamine treatment-resistant patients with MDD. Considering NMDA-R antagonists (traxoprodil, lanicemine, rapasti- the role of dopamine release in psychosis, it is likely nel) in patients with major depressive disorder (MDD) that marked release of dopamine from presynaptic and bipolar disorder. The authors examined the time terminals in the striatum could be associated with trajectory of efficacy of ketamine and non-ketamine psychotomimetic side effects in humans after a single NMDA-R antagonists. The greater reduction in depres- infusion of ketamine or esketamine. sive symptoms by ketamine infusion started as early The authors also pointed out that the transient as within 40–60 min, peaking on day 1, and lasting efficacy lasting 1 week post-infusion of ketamine has sti- until days 5–8, with maintenance of superior remission mulated multi-infusion studies (Kishimoto et al.
    [Show full text]
  • 'Party Drug' Turned Antidepressant Approaches Approval
    NEWS & ANALYSIS Nature Reviews Drug Discovery | Published online 30 Oct 2018; doi:10.1038/nrd.2018.187 ‘Party drug’ turned anti depressant approaches approval Johnson & Johnson has submitted its esketamine for regulatory approval, but researchers still don’t understand how the fast-acting antidepressant lifts moods. DrAfter123/DigitalVision Vectors Sara Reardon Monteggia, a neuroscientist at Vanderbilt later learned that the antibiotic, at low doses, University. blocks the NMDA receptor, a glutamate When researchers showed in 2006 that the Yet it is far from clear how this work will receptor. Then in the late 1990s,Nature when Reviews | Drug Discovery anaesthetic ketamine — also known as the play out. Whereas early evidence suggested psychiatrist John Krystal of Yale University club drug Special K — was a rapid and potent that ketamine acted through the NMDA was curious about whether the antidepressant, big pharmaceutical receptor, many of the first-generation neurotransmitter glutamate contributed to companies quickly jumped into the game. ketamine mimetics that were designed to act schizophrenia, he decided to test the known Extensive efforts to improve on decades-old on this target failed in clinical trials (TABLE 1). NMDA receptor antagonist ketamine in nine antidepressants had floundered, but ketamine Accumulating evidence now suggests that depressed patients. finally promised a novel mechanism of action ketamine’s antidepressant activity may be At the time, glutamate had mostly been and the potential to help treatment-resistant more complicated. studied for its role in learning and memory. But patients. As a result, some companies are quietly Krystal’s group found that ketamine induced a Because ketamine is an old drug and going back to the drawing board.
    [Show full text]